Clinical trials
Uveitis, Posterior trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 5 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Terminated | 13 |
| Unknown status | 8 |
| Withdrawn | 6 |
| Not yet recruiting | 2 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| Clearside Biomedical, Inc. | 5 |
| Allergan | 3 |
| National Eye Institute (NEI) | 3 |
| XOMA (US) LLC | 3 |
| EyePoint Pharmaceuticals, Inc. | 2 |
| Johns Hopkins University | 2 |
| Lux Biosciences, Inc. | 2 |
| Novartis | 2 |
| Texas Retina Associates | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uveitis, Posterior | 60 |
| Uveitis, Intermediate | 40 |
| Uveitis | 39 |
| Panuveitis | 27 |
| Uveitis, Anterior | 9 |
| Behcet Syndrome | 7 |
| Macular Edema | 6 |
| Retinal Vasculitis | 4 |
| Birdshot Chorioretinopathy | 2 |
| Choroidal Effusions | 2 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.